Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTXNASDAQ:LGVNNASDAQ:LPCNNASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$0.30-3.1%$0.34$0.22▼$2.54$18.49M0.752.73 million shs542,536 shsLGVNLongeveron$1.30-1.5%$1.41$1.14▼$6.40$19.41M0.221.50 million shs312,082 shsLPCNLipocine$3.12-1.3%$3.27$2.68▼$11.79$16.69M1.3436,855 shs12,166 shsRDHLRedHill Biopharma$1.75-9.8%$2.06$1.71▼$20.28$4.01M4.23164,327 shs44,590 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-3.15%+1.02%-10.55%-33.33%-87.47%LGVNLongeveron-1.52%+5.69%-3.70%-23.08%-28.18%LPCNLipocine-1.27%-0.64%-1.27%-6.87%-60.75%RDHLRedHill Biopharma-9.79%-12.06%-6.91%-31.64%-99.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGTXCognition Therapeutics3.6453 of 5 stars3.55.00.00.03.01.71.3LGVNLongeveron3.5071 of 5 stars3.65.00.00.02.01.71.3LPCNLipocine2.1534 of 5 stars3.53.00.00.02.50.00.6RDHLRedHill Biopharma1.0725 of 5 stars0.05.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 3.00Buy$5.631,785.69% UpsideLGVNLongeveron 3.25Buy$8.67566.67% UpsideLPCNLipocine 3.00Buy$9.00188.46% UpsideRDHLRedHill Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RDHL, CGTX, LGVN, and LPCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/29/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.005/27/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.005/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.003/24/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.003/21/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/ALGVNLongeveron$2.23M8.72N/AN/A$2.68 per share0.49LPCNLipocine$3.67M4.54N/AN/A$3.83 per share0.81RDHLRedHill Biopharma$8.04M0.50$175.00 per share0.01$40.58 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$25.79M-$0.74N/AN/AN/AN/A-150.93%-100.82%8/6/2025 (Estimated)LGVNLongeveron-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%8/13/2025 (Estimated)LPCNLipocine-$16.35M-$1.02N/A∞N/AN/A-19.17%-17.60%8/6/2025 (Estimated)RDHLRedHill Biopharma$23.92MN/A0.00∞N/AN/AN/AN/A6/14/2025 (Estimated)Latest RDHL, CGTX, LGVN, and LPCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2024LPCNLipocine-$0.35-$0.35N/A-$0.35$0.35 million$0.09 million5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12-$0.14-$0.02-$0.14N/AN/A3/20/2025Q4 2024CGTXCognition Therapeutics-$0.16-$0.17-$0.01-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ARDHLRedHill BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A2.112.11LGVNLongeveronN/A7.677.67LPCNLipocineN/A12.9712.97RDHLRedHill BiopharmaN/A0.740.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%LGVNLongeveron10.01%LPCNLipocine9.11%RDHLRedHill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics14.40%LGVNLongeveron11.20%LPCNLipocine6.35%RDHLRedHill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2061.99 million32.93 millionNot OptionableLGVNLongeveron2014.93 million12.00 millionNot OptionableLPCNLipocine105.35 million5.02 millionNo DataRDHLRedHill Biopharma2102.29 million1.19 millionNo DataRDHL, CGTX, LGVN, and LPCN HeadlinesRecent News About These CompaniesRedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment WinMay 13, 2025 | prnewswire.comRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology CongressMay 2, 2025 | prnewswire.comRedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107April 28, 2025 | prnewswire.comRedHill Biopharma receives non-compliance letter from NasdaqApril 18, 2025 | markets.businessinsider.comRedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 18, 2025 | finanznachrichten.deRedHill Biopharma announces publication in journal on OpaganibApril 17, 2025 | markets.businessinsider.comRedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity DeficiencyApril 17, 2025 | prnewswire.comRedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market DisruptionApril 16, 2025 | prnewswire.comRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | finanznachrichten.deRedHill Biopharma Announces Full-Year 2024 Financial Results and Operational HighlightsApril 10, 2025 | prnewswire.comRedHill Biopharma to submit UK MAA for TaliciaMarch 18, 2025 | markets.businessinsider.comRedHill to file FDA-approved Talicia for UK marketingMarch 18, 2025 | thepharmaletter.comRedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing AuthorisationMarch 18, 2025 | finanznachrichten.deRedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing AuthorisationMarch 18, 2025 | prnewswire.comRedHill Biopharma announces plans to advance program for Crohn’s diseaseMarch 13, 2025 | markets.businessinsider.comRedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 ResultsMarch 12, 2025 | prnewswire.comRedHill Presents Business Update at the Sachs' European Life Sciences CEO ForumFebruary 27, 2025 | prnewswire.comRedHill and Hyloris sign agreement for Bekinda’s developmentFebruary 26, 2025 | msn.comRedHill Licenses RHB-102 to HylorisFebruary 25, 2025 | contractpharma.comRedHill Biopharma licenses RHB-102 for global commercialization to HylorisFebruary 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRDHL, CGTX, LGVN, and LPCN Company DescriptionsCognition Therapeutics NASDAQ:CGTX$0.30 -0.01 (-3.15%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.30 +0.00 (+0.91%) As of 06/13/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Longeveron NASDAQ:LGVN$1.30 -0.02 (-1.52%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.33 +0.03 (+2.38%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Lipocine NASDAQ:LPCN$3.12 -0.04 (-1.27%) Closing price 06/13/2025 03:52 PM EasternExtended Trading$3.14 +0.02 (+0.61%) As of 06/13/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.RedHill Biopharma NASDAQ:RDHL$1.75 -0.19 (-9.79%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$1.76 +0.01 (+0.57%) As of 06/13/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
